Emerging analgesics in cancer pain management

Expert Opinion on Emerging Drugs

Volumn 10, Issue 1, 2005, Pages 151-171

  Radbruch, Lukas ^a   Elsner, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cannabinoids; COX 2 selective NSAIDs; Nitric oxide; NMDA antagonists; Opioids

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CANNABINOID; CARBAMAZEPINE; CONOTOXIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DIPYRONE; FENTANYL; GABAPENTIN; GLYCERYL TRINITRATE; KETAMINE; LEVOMETHADONE; MEMANTINE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC AGENT; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXCARBAZEPINE; OXYCODONE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALGORITHM; ANALGESIA; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DROWSINESS; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HALLUCINATION; HUMAN; NEUROPATHIC PAIN; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT;

ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE MANAGEMENT; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; PAIN;

EID: 14344249107     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.1.151     Document Type: Review

References (161)

1. BONICA JJ: Cancer Pain. In Management of Pain. Bonica JJ (ed.) Lea & Febiger, Philadelphia (1990): 400-460.
2. ZECH DF, GROND S, LYNCH J, HERTEL D, LEHMANN KA: Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain (1995) 63:65-76.
3. CARACENI A, PORTENOY RK, ASHBY MA et al.: An internarional survey of cancer pain characterisrics and syndromes. Pain (1999) 82(3):263-274.
4. COYLE N: In their own words: seven advanced cancer patients describe their experience wirh pain and the use of opioid drugs. J. Pain Symptom Manage. (2004) 27(4):300-309.
5. KUSNECOV AW, RABIN BS: Stressor-induced alterations of immune function: mechanisms and issues. Int. Arch. Allergy Immunol. (1994) 105(2):107-121.
6. WORLD HEALTH ORGANIZATION: Cancer pain relief: with a guide to opioid availability. WHO (ed.) WHO, Geneva, (1996).
7. DE STOUTZ ND, BRUERA E, SUAREZ-ALMAZOR M: Opioid rotarion for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage. (1995) 10(5):378-384.
8. HAWLEY P, FORBES K, HANKS GW: Opioids, confusion and opioid rotation. Palliat. Med. (1998) 12:63-64.
9. MERCADANTE S, RADBRUCH L, CARACENI A et al.: Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer (2002) 94(3):832-839.
10. GROND S, ZECH D, DIEFENBACH C, BISCHOFF A: Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J. Pain Symptom Manage. (1994) 9:372-382.
11. JADAD AR, BROWMAN GP: The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA (1995) 274(23):1870-1873.
12. BRUNSCH-RADBRUCH A, RADBRUCH L, STEDEN E et al.: Transdermales fentanyl in der klinischen Praxis - eine Anwendungsbeobachrung. Schmerz (1997) 11(Suppl.1):S53.
13. BÖGER RH, SCHMIDT G: Analgerika. In Arneiverordnungsreport 2001. Schwabe U et al. (eds) Springer, Berlin (2001):89-102.
14. SCHMIDT G: Analgetika. In Arzneiverordnungsreport 1991. Schwabe U et al. (eds) Gustav Fischer Verlag, Stuttgart (1991):20-31.
15. NAUCK F, OSTGATHE C, KLASCHIK E et al.: Drugs in palliative care: results from a represenrative survey in Germany. Palliat. Med. (2004) 18(2):100-107.
16. LEHMANN KA, RADBRUCH L, GOCKEL HH, NEIGHBORS D, NUYTS G: Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur. J. Healh. Econom. (2002) 3:111-119.
17. HANKS G, PORTENOY RK, MACDONALD N, FORBES K: Difficult pain problems. In Oxford Textbook of Palliat. Med. Doyle D et al. (eds) Oxford Medical Publications, Oxford (1998):454-477.
18. MANTYH PW, CLOHISY DR, KOLTZENBURG M, HUNT SP: Molecular mechanisms of cancer pain. Nat. Rev Cancer (2002) 2(3):201-209.
19. HONORE P, SCHWEI J, ROGERS SD et al.: Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog. Brain Res. (2000) 129:389-397.
20. REGAN JM, PENG P: Neurophysiology of cancer pain. Cancer Control (2000) 7(2):111-119.
21. AHMAD SR, KORTEPETER C, BRINKER A, CHEN M, BEITZ J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. (2002) 25(7):537-544.
22. WARNER TD, MITCHELL JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb. J. (2004) 18(7):790-804.
23. HARVEY RJ, DEPNER UB, WASSLE H et al.: GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 304(5672):884-887.
24. KISMET K, AKAY MT, ABBASOGLU O, ERCAN A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prev. (2004) 28(2):127-142.
25. DAVIS TW, ZWEIFEL BS, O'NEAL JM et al.: Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J. Pharmacol. Exp. Ther. (2004) 308(3):929-934.
26. WOLFE F, ZHAO S, PETTITT D: Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J. Rheumatol. (2004) 31(6):1143-1151.
27. RAY WA, STEIN CM, DAUGHERTY JR et al.: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360(9339):1071-1073.
28. WHELTON A, WHITE WB, BELLO AE, PUMA JA, FORT JG: Effects of celecoxib and rofecoxib on blood pressure and edema in parients > or =65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. (2002) 90(9):959-963.
29. MAMDANI M, JUURLINK DN, LEE DS et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet (2004) 363(9423):1751-1756.
30. BALLANTYNE JC, MAO J: Opioid therapy for chronic pain. N. Engl. J. Med. (2003) 349(20):1943-1953.
31. HANKS GW, DECONNO F, CHERNY N et al.: Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer (2001) 84:587-593.
32. TEGEDER I, GEISSLINGER G: Einsatz von Opioiden bei Leber- oder Niereninsuffizienz. Schmerz (1999) 13:183-195.
33. LIKAR R, GRIESSINGER N, SADJAK A, SITTL R: Transdermal buprenorphine for treatment of chronic tumour and non-tumour pain. Wien. Med. Wochenschr. (2003) 153(13-14):317-322.
34. BOHME K, BLOMS-FUNKE P, GILLEN C, SCHUETTLER AJ, WNENDT S: Buprenorphine in a transdermal therapeutic system-a new option. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Clin. Rheumatol. (2002) 21(Suppl. 1)(7):S13-S16.
35. GOBEL H, STADLER T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs (1997) 53(Suppl. 2):34-39.
36. DELLEMIJN PL, VANNESTE JA: Randomised double-blind active-placebo- controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet (1997) 347:753-758.
37. MEGENS AA, ARTOIS K, VERMEIRE J, MEERT T, AWOUTERS FH: Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J. Pain Symptom Manage. (1998) 15(4):253-258.
38. AHMEDZAI S, BROOKS D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J. Pain Symptom Manage. (1997) 13:254-261.
39. ALLAN L, HAYS H, JENSEN NH et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ (2001) 322(7295):1154.
40. MUCCI-LORUSSO P, BERMAN BS, SILBERSTEIN PT et al.: Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur. J. Pain (1998) 2(2):239-249.
41. MADDOCKS I, SOMOGYI A, ABBOTT F, HAYBALL P, PARKER D: Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J. Pain Symptom Manage. (1996) 12(3):182-189.
42. HIROTA T, IEIRI I, TAKANE H et al.: Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos. (2003) 31(5):677-680.
43. ROSS FB, SMITH MT: The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain (1997) 73(2):151-157.
44. YOBURN BC, SHAH S, CHAN K, DUTTAROYA, DAVIS T: Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol. Biochem. Behav. (1995) 51(2-3):535-539.
45. NIELSEN CK, ROSS FB, SMITH MT: Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J. Pharmacol. Exp. Ther. (2000) 295(1):91-99.
46. GORMAN AL, ELLIOTT KJ, INTURRISI CE: The d- and 1-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. (1997) 223(1):5-8.
47. SHIMOYAMA N, SHIMOYAMA M, ELLIOTT KJ, INTURRISI CE: D-Methadone is antinociceptive in the rat formalin test. J. Pharmacol. Exp. Ther. (1997) 283(2):648-652.
48. CARPENTER KJ, CHAPMAN V, DICKENSON AH: Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. Eur. J. Pain (2000) 4(1):19-26.
49. RADY JJ, HOLMES BB, PORTOGHESE PS, FUJIMOTO JM: Morphine tolerance in mice changes response of heroin from mu to delta opioid receptors. Proc. Soc. Exp. Biol. Med. (2000) 224(2):93-101.
50. CICHEWICZ DL, MARTIN ZL, SMITH FL, WELCH SP: Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther. (1999) 289(2):859-867.
51. WILLERT RP, WOOLF CJ, HOBSON AR, et al.: The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology (2004) 126(3):683-692.
52. BURSZTAJN S, RUTKOWSKI MD, DELEO JA: The role of the N-methyl-D-aspartate receptor NR1 subunit in peripheral nerve injury-induced mechanical allodynia, glial activation and chemokine expression in the mouse. Neuroscience (2004) 125(1):269-275.
53. MERCADANTE S, LODI F, SAPIO M, CALLIGARA M, SERRETTA R: Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J. Pain Symptom Manage. (1995) 10(7):564-568.
54. KANNAN TR, SAXENA A, BHATNAGAR S, BARRY A: Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J. Pain Symptom Manage. (2002) 23(1):60-65.
55. MERCADANTE S, ARCURI E, TIRELLI W, CASUCCIO A: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J. Pain Symptom Manage. (2000) 20(4):246-252.
56. BROADLEY KE, KUROWSKA A, TOOKMAN A: Ketamine injection used orally. Palliat. Med. (1996) 10(3):247-250.
57. LAURETTI GR, LIMA IC, REIS MP, PRADO WA, PEREIRA NL: Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology (1999) 90(6):1528-1533.
58. PUD D, EISENBERG E, SPITZER A et al.: The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain (1998) 75(2-3):349-354.
59. Memantine in the treatment of diabetics with painful peripheral neuropathy: a placebo-controlled phase IIb trial. Pain Med (2002) 3(2):182.
60. EISENBERG E, KLEISER A, DORTORT A, HAIM T, YARNITSKY D: The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur. J. Pain (1998) 2(4):321-327.
61. MAIER C, DERTWINKEL R, MANSOURIAN N et al.: Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain (2003) 103(3):277-283.
62. NIKOLAJSEN L, GOTTRUP H, KRISTENSEN AG, JENSEN TS: Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth. Analg. (2000) 91(4):960-966.
63. WIECH K, KIEFER RT, TOPFNER S et al.: A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth. Analg. (2004) 98(2):408-413, table of contents.
64. MERCADANTE S, CASUCCIO A, GENOVESE G: Ineffectiveness of dextromethorphan in cancer pain. J. Pain Symptom Manage. (1998) 16(5):317-322.
65. KATZ NP: MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients. J. Pain Symptom Manage. (2000) 19(Suppl. 1):S37-S41.
66. BEN ABRAHAM R, MAROUANI N, WEINBROUM AA: Dextromethorphan mitigates phantom pain in cancer amputees. Ann. Surg. Oncol. (2003) 10(3):268-274.
67. WEINBROUM AA, BENDER B, BICKELS J et al.: Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement: a randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated patients. Cancer (2003) 97(9):2334-2340.
68. EBERT B, THORKILDSEN C, ANDERSEN S, CHRISTRUP LL, HJEDS H: Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem. Pharmacol. (1998) 56(5):553-559.
69. MAKIN MK, ELLERSHAW JE: Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer. BMJ (1998) 317(7150):81.
70. BRAGA MF, ARONIADOU-ANDERJASKA V, POST RM, LI H: Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. Neuropharmacology (2002) 42(4):522-529.
71. ASHTON H, YOUNG AH: GABA-ergic drugs: exit stage left, enter stage right. J. Psychopharmacol. (2003) 17(2):174-178.
72. LAUGHLIN TM, TRAM KV, WILCOX GL, BIRNBAUM AK: Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J. Pharmacol. Exp. Ther. (2002) 302(3): 1168-1175.
73. JASMIN L, TIEN D, JANNI G, OHARA PT: Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain (2003) 106(1-2):3-8.
74. CANAVERO S, BONICALZI V: Norepinephrine and pain. Pain (2004) 107(3):279.
75. LYNCH ME: Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. (2001) 26(1):30-36.
76. DURAND JP, GOLDWASSER F: Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anti-Cancer Drugs (2002) 13(7):777-780.
77. VENTAFRIDDA V, BONEZZI C, CARACENI A et al.: Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. Ital. J. Neurol. Sci. (1987) 8(6):579-587.
78. EHRNROOTH E, GRAU C, ZACHARIAE R, ANDERSEN J: Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol. (2001) 40(6):745-750.
79. ELPHICK MR, EGERTOVA M: The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1407):381-408.
80. SMITH FL, CICHEWICZ D, MARTIN ZL, WELCH SP: The enhancement of morphine actinociception in mice by delta9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. (1998) 60(2):559-566.
81. WELCH SP, EADS M: Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. (1999) 848(1-2):183-190.
82. MENG ID, MANNING BH, MARTIN WJ, FIELDS HL: An analgesia circuit activated by cannabinoids. Nature (1998) 395(6700):381-383.
83. CAMPBELL FA, TRAMER MR, CARROLL D et a.: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ (2001) 323(7303):13-16.
84. STAATS PS, YEARWOOD T, CHARAPATA SG et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA (2004) 291(1):63-70.
85. DOGGRELL SA: Intrathecal ziconotide for refractory pain. Expert Opin. Investig. Drugs (2004) 13(7):875-877.
86. FERREIRA SH: The tole of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs (1993) 46(Suppl. 1):1-9.
87. SACHS D, CUNHA FQ, FERREIRA SH: Periphetal analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc Natl. Acad. Sci. USA (2004) 101(10):3680-3685.
88. VIVANCOS GG, PARADA CA, FERREIRA SH: Opposite nociceptive effects of the arginine/NO/cGMP pathway stimulation in dermal and subcutaneous tissues. Br. J. Pharmacol. (2003) 138(7):1351-1357.
89. STICHTENOTH DO: The second generation of COX-2 inhibitors: clinical pharmacological point of view. Mini Rev. Med. Chem. (2004) 4(6):617-624.
90. FOX A, MEDHURST S, COURADE JP et al.: Anti-hyperalgesic activity of the COX-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain (2004) 107(1-2):33-40.
91. FIORUCCI S, ANTONELLI E, BURGAUD JL, MORELLI A: Nitric oxide-releasing NSAIDs: a review of their current status. Drug Saf. (2001) 24(11):801-811.
92. YEH RK, CHEN J, WILLIAMS JL et al.: NO-donating nonsteroidal antiinflammatoty drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. Pharmacol. (2004) 67(12):2197-2205.
93. JONZON B, BJARNASON I, HAWKEY C et al.: The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology (2003) 11(4):437-444.
94. HOOGSTRAATE J, ANDERSSON LI, BERGE OG, JONZON B, OJTEG G: COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. Inflammopharmacology (2003) 11(4):423-428.
95. WENK GL, ROSI S, MCGANN K, HAUSS-WEGRZYNIAK B: A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Eur. J. Pharmacol. (2002) 453(2-3):319-324.
96. VANBEVER R, LANGERS G, MONTMAYEUR S, PREAT V: Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation. J. Controlled Release (1998) 50(1-3):225-235.
97. STRIEBEL HW, OLMANN T, SPIES C, BRUMMER G: Patient-controlled intranasal analgesia (PCINA) for the management of postperative pain: a pilot study. J. Clin. Anestesia (1996) 8:5-8.
98. BEYSSAC E, TOUAREF F, MEYER M et al.: Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm. Drug Dispos. (1998) 19(6):401-405.
99. TASKER RA, CONNELL BJ, ROSS SJ, ELSON CM: Development of an injectable sustained-release formulation of morphine: antinociceptive properties in rats. Lab. Anim. (1998) 32(3):270-275.
100. BES JC, TKACZUK J, CZECH KA et al.: One-year chromaffin cell allograft survival in cancer patients with chronic pain: morphological and functional evidence. Cell Transplant. (1998) 7(3):227-238.
101. BUCHSER E, GODDARD M, HEYD B et al.: Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience [published erratum appears in Anesthesiology 1997 Feb; 86(2):509]. Anesthesiology (1996) 85(5):1005-1012; discussion 1029A-1030A.
102. BUCHSER E, GODDARD M, HEYD B et al.: Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience [published erratum appears in Anesthesiology 1997 Feb; 86(2):509]. Anesthesiology (1996) 85(5):1005-1012; discussion 1029A-1030A.
103. ROMBERG R, OLOFSEN E, SARTON E et al.: Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucutonide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology (2004) 100(1):120-133.
104. ROMBERG R, SARTON E, TEPPEMA L et al.: Comparison of morphine-6- glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br. J. Anaesth. (2003) 91(6):862-870.
105. FADDA P, BARLOCCO D, TRONCI S, CIGNARELLA G, FRATTA W: Antinociceptive action of DBO 17 and DBO 11 in mice: two 3,8 diazabicyclo (3.2.1.) octane derivates with selective mu opioid receptor affinity. Naunyn Schmiedebergs Arch. Pharmacol. (1997) 356(5):596-602.
106. BURKEY TH, EHLERT FJ, HOSOHATA Y et al.: The efficacy of delta-opioid receptor-selective drugs. Life Sci. (1998) 62(17-18):1531-1536.
107. MARIE N, LANDEMORE G, DEBOUT C, JAUZAC P, ALLOUCHE S: Pharmacological characterization of AR-M1000390 at human delta opioid receptors. Life Sci. (2003) 73(13):1691-1704.
108. SHAPIRA M, KEREN O, GAFNI M, SARNE Y: Divers pathways mediate delta-opioid receptor down regulation within the same cell. Brain Res. Mol. Brain Res. (2001) 96(1-2):142-150.
109. ZADINA JE, HACKLER L, GE LJ, KASTIN AJ: A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 386(6624):499-502.
110. TAYLOR F, DICKENSON A: Nociceptin/orphanin FQ. A new opioid, a new analgesic? Neuroreport (1998) 9(12):R65-R70.
111. ZAVERI N: Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. (2003) 73(6):663-678.
112. MORK H, HOMMEL K, UDDMAN R, EDVINSSON L, JENSEN R: Does nociceptin play a role in pain disorders in man? Peptides (2002) 23(9):1581-1587.
113. MEUNIER JC: Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur. J. Pharmacol. (1997) 340(1):1-15.
114. JUDD AK, KAUSHANSKAYA A, TUTTLE DJ et al.: N-terminal modifications leading to peptide ORL1 partial agonists and antagonists. J. Pept. Res. (2003) 62(5):191-198.
115. YAMADA H, NAKAMOTO H, SUZUKI Y, ITO T, AISAKA K: Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801. Br. J. Pharmacol. (2002) 135(2):323-332.
116. PARSONS CG, DANYSZ W, QUACK G: Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists-in vitro characterisation. Amino Acids (2000) 19(1):157-166.
117. BOYCE S, WYATT A, WEBB JK et al.: Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology (1999) 38(5):611-623.
118. CHAZOT PL: The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem. (2004) 11(3):389-396.
119. SMITH PF: Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? Curr. Opin. Investig. Drugs (2003) 4(7):826-832.
120. STAHL SM: Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J. Clin. Psychiatry (2004) 65(5):596-597.
121. SABATOWSKI R, GALVEZ R, CHERRY DA et al.: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain (2004) 109(1-2):26-35.
122. MCCLEANE G, KOCH B, RAUSCHKOLB C: Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study. Neurosci. Lett. (2003) 352(2):117-120.
123. DOST R, ROSTOCK A, RUNDFELDT C: The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(4):382-390.
124. KAMINSKI RM, LIVINGOOD MR, ROGAWSKI MA: Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia (2004) 45(7):864-867.
125. SHIN SW, EISENACH JC: Peripheral nerve injury sensitizes the response to visceral distension but not its inhibition by the antidepressant milnacipran. Anesthesiology (2004) 100(3):671-675.
126. LEO RJ, BARKIN RL: Antidepressant use in chronic pain management: is there evidence of a role for duloxetine? Prim. Care Companion J. Clin. Psychiatry (2003) 5(3):118-123.
127. FOX A, KESINGLAND A, GENTRY C et al.: The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 92(1-2):91-100.
128. GUHRING H, SCHUSTER J, HAMZA M et al.: HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur. J. Pharmacol. (2001) 429(1-3):127-134.
129. BRIDGES D, AHMAD K, RICE AS: The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol. (2001) 133(4):586-594.
130. VALIVETI S, KIPTOO PK, HAMMELL DC, STINCHCOMB AL: Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro. Int. J. Pharm. (2004) 278(1):173-180.
131. ZHAN J, CHEN X, WANG C et al.: A fusion protein of conotoxin MVIIA and thioredoxin expressed in Escherichia coli has significant analgesic activity. Biochem. Biophys. Res. Commun. (2003) 311(2):495-500.
132. Does frog toxin represent a giant leap for treatment of pain? [news]. Gastroenterology (1998) 114(3):430.
133. WU WP, HAO JX, ONGINI E et al.: A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury. Br. J. Pharmacol. (2004) 141(1):65-74.
134. ROMERO-SANDOVAL EA, MAZARIO J, HOWAT D, HERRERO JF: NCX-701 (nitroparacetamol) is an effective antinociceptive agent in rat withdrawal reflexes and wind-up. Br. J. Pharmacol. (2002) 135(6):1556-1562.
135. MOORE PK, MARSHALL M: Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig. Liver Dis. (2003) 35(Suppl. 2):S49-S60.
136. BERGER V, ALLOUI A, KEMENY JL et al.: Evidence for a role for bulbospinal pathways in the spinal antinociceptive effect of systemically administered vapreotide in normal rats. Fundam. Clin. Pharmacol. (1998) 12(2):200-204.
137. DECKER MW, MEYER MD: Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem. Pharmacol. (1999) 58(6):917-923.
138. PEUCKMANN V, STRUMPF M, ZENZ M, BRUERA E: [Novel potential uses of thalidomide in the management of pain? A review of the literature]. Schmerz (2003) 17(3):204-210.
139. SZALLASI A: Vanilloid recepror ligands: hopes and realities for the future. Drugs Aging (2001) 18(8):561-573.
140. ROBBINS WR, STAATS PS, LEVINE J et al.: Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth. Analg. (1998) 86(3):579-583.
141. PAICE JA, FERRANS CE, LASHLEY FR et al.: Topical capsaicin in the management of HIV-associated peripheral neuropathy. J. Pain Symptom Manage. (2000) 19(1):45-52.
142. MCEWAN AJ: Use of radionuclides for the palliation of bone metastases. Semin. Radiat. Oncol. (2000) 10(2):103-114.
143. DAFERMOU A, COLAMUSSI P, GIGANTI M et al.: A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. J. Nucl. Med. (2001) 28(7):788-798.
144. SARTOR O, REID RH, HOSKlN PJ et al.: Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology (2004) 63(5):940-945.
145. LIEPE K, KROPP J, RUNGE R, KOTZERKE J: Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br. J. Cancer (2003) 89(4):625-629.
146. WINDSOR PM: Predictors of response to strontium-89 (Merastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin. Oncol. (R Coll Radiol) (2001) 13(3):219-227.
147. PATRIGNANI P, CAPONE ML, TACCONELLI S: Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin. Pharmacother. (2003) 4(2):265-284.
148. KELLSTEIN D, OTT D, JAYAWARDENE S, FRICKE J: Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int. J. Clin. Pract. (2004) 58(3):244-250.
149. KEEBLE JE, MOORE PK: Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. (2002) 137(3):295-310.
150. HOUGHTON AK, PARSONS CG, HEADLEY PM: Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. Pain (2001) 91(3):201-207.
151. LUTFY K, DOAN P, WEBER E: ACEA-1328, a NMDA receptor/glycine site antagonist, acutely potentiates antinociception and chronically attenuates tolerance induced by morphine. Pharmacol. Res. (1999) 40(5):435-442.
152. WALTERS MR, BRADFORD AP, FISCHER J, LEES KR: Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br. J. Clin. Pharmacol. (2002) 53(3):305-311.
153. DE VRY J, KUHL E, FRANKENKUNKEL P, ECKEL G: Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur. J. Pharmacol. (2004) 491(2-3):137-148.
154. TOYOFUKU A, MIYAKO H: A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. Hum. Psychopharmacol. (2004) 19(5):357-358.
155. DAJANI EZ, LARSEN KR, TAYLOR J et al.: 1,1-Dimethylheptyl-delta-8- tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J. Pharmacol. Exp. Ther. (1999) 291(1):31-38.
156. SCOTT DA, WRIGHT CE, ANGUS JA: Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur. J. Pharmacol. (2002) 451(3):279-286.
157. DAI Q, LIU F, ZHOU Y et al.: The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus. J. Nat. Prod. (2003) 66(9):1276-1279.
158. DI NAPOLI M, PAPA F: NCX-4016 NicOx. Curr. Opin. Investig. Drugs (2003) 4(9):1126-1139.
159. MARIOTTO S, CUZZOLIN L, ADAMI A et al.: Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. Br. J. Pharmacol. (1995) 115(2):225-226.
160. ROSSONI G, MANFREDI B, DEL SOLDATO P, BERTI F: The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J. Pharmacol. Exp. Ther. (2004) 310(2):555-562.
161. WORLD HEALTH ORGANIZATION: Cancer pain relief: with a guide to opioid availability, (ed.) World Health Organization, Genf, (1996).